A strong heritage and
an ambitious future

50-year track record

Based in Switzerland and privately-owned, Labatec is a pharmaceutical company with a 50-year track record of delivering high quality products to European and Emerging markets.

Trusted European brand

Meeting the needs of the hospital and retail sectors, we deliver medicines that help to improve quality of life for patients around the world. Manufactured in Europe and approved by Swissmedic medicinal agency, our products represent a trusted European brand of medicines.

Injectables and orals products

Our growing product portfolio includes injectables and orals for hospital use, speciality retail products in multiple therapeutic areas, including musculo-skeletal and women’s health, and an OTC range to complement our prescription portfolio.

Our footprint

In addition to our own local teams in the Middle East North Africa Region (MENA) and Switzerland, we work with a vast network of local distribution agencies to rapidly register and drive the launch of new products. Our experienced local teams draw on their deep understanding of local markets to maximize the value of our partners’ products.




Originally incorporated in Geneva in 1957, the company was acquired in 2008 by Dr Samih Darwazah, the founder of the global pharmaceutical business Hikma Pharmaceuticals PLC (LON:HIK). It remains today a family privately owned business.


Expansion in
Emerging Markets

Under the company’s new management team, Labatec expanded its business fivefold within eight years through the successful development of the injectables hospital business in Switzerland, and the introduction of our well established Swiss brands in the MENA region.



In 2016, Labatec entered a new development phase, appointing a new board of directors consisting of high profile pharma and business executives, and reinforcing the management team in several key positions.

The company is now poised for significant growth through the acquisition of products and companies, in parallel with its reinforced in-licensing strategy.


15 countries
NOW expanding into the EU

Since its acquisition in 2008, Labatec has rapidly expanded from its Swiss base to the emerging markets region, entering 14 new countries in the last eight years, with presence in both retail and hospital segments.

With its strong track record of success in new markets and geographies, and in line with its mission of ‘Valuing Life’, Labatec is now expanding into the EU, bringing its high quality products to an even broader range of patients.

Key features of
Labatec, our DNA

  • Solid track record of delivering Swiss-branded high quality products to our communities,
    making us a trusted healthcare partner across the regions where we operate in
  • Private company with an agile organization
    which enables us to effectively establish strategic partnerships, rapidly register products with Swiss and Emerging Markets health authorities, and handle frequent product launches in our regions
  • Up-to-date understanding of local market needs in Emerging Markets, Switzerland and neighbouring EU countries, ensuring we continue to deliver relevant and innovative products across a wide range of indications


  • Excellence
  • Integrity
  • Collaboration
  • Accountability
  • Creativity

We put the quality of our products and processes first.

We strive to continuously improve the value delivered to our customers
and partners through an agile organization

We adapt to a fast changing environment.

We are transparent, honest and ethical in all our interactions with employees, clients and partners.

We seek to inspire trust and respect with our counterparts.

We act fairly, within the spirit of all laws, regulations and policies.

We collaborate to deliver outcomes which add significant value to our clients’ projects and the community as a whole.

We treat people with consideration and value ideas on their merit.

We strive for diversity within our team, and do not discriminate anyone on the basis of race, ethnicity, national origin, religion, gender identity or ability.

We take personal responsibility for our actions and results.

We keep promises and commitments made to others.

We encourage our team to be curious and perceive the world in new ways, to find new paths and to generate innovative solutions.


Management Team

  • Faisal Darwazeh


    After spending seven years at GE Healthcare in the United States in various functions in supply chain, consulting and services, Faisal joined Labatec Switzerland in early 2010. Together with the new management team, his role was to build a growing specialty pharma company in Europe and Emerging Markets.

    Faisal holds a BSc in Industrial Engineering from Marquette University and an MBA from Duke University.
  • Viktoria Stepanova

    Director of Global Strategy & Business Development

    After spending five years as a management consultant at McKinsey&Co where she worked with leading global pharma companies to define their corporate and business unit growth strategies, Viktoria now leads strategy, business development and partnering activities at Labatec, helping the company to expand its portfolio and geographic footprint.

    Viktoria holds a Master of Science degree in bioengineering and medical technology as well as an MBA from INSEAD (14J).
  • Francois Detraz

    Commercial Director, Switzerland

    François has over 25 years’ experience in the pharmaceutical sector, working with a broad base of partners and in a wide variety of medical specialties. Following roles with Daiichi Sankyo, Eli Lilly and Eisai, he was appointed as Sales Director at Labatec in 2009 and has been Commercial Director since 2013.

    François’s areas of expertise include marketing, people development, sales and account management, and new product launches. He has a proven track record of delivering sustainable results in high growth environments.
  • Said Arar

    General Manager Emerging Markets

    With over 20 years’ experience at Hikma Pharmaceuticals PLC, Said has occupied executive positions in MENA across various major markets in the region. Said is now managing the Labatec Emerging Markets business, working towards expanding our geographical presence, and helping to increase our market share and advance our growth in the region.

    Said holds a BSc degree in Science from the University of Jordan and an EMBA from the American University of Beirut.
  • Muriel Xatard

    Head of Supply Chain

    After nine years at Novartis in various operational roles, Muriel joined Labatec nine years ago. She started as Quality Assurance manager before taking over the management of Labatec’s manufacturing site based in Meyrin.

    Since 2017, Muriel has led the supply chain department and customer services function, helping the company to improve customer satisfaction.
  • Basil Nofal

    Technical Director, Quality Assurance and Qualified Person

    Basil has a breadth of experience gained during his 15 years at Hikma Pharmaceuticals PLC where he was involved in a range of business areas across EMEA and US. His role as Technical Director and Qualified Person at Labatec involves him in developing new, high quality products which fulfill international quality standards and meet customers’ needs.

    Basil holds a Bachelor in Pharmacy and is a certified Project Management Professional (PMP) from PMI Pennsylvania, United States.
  • Fanny Lazzarotto

    Director of Human Resources

    Fanny has been Human Resources (HR) Director of Labatec since 2015, working across all the functional disciplines of HR across our regions. Prior to joining the company, she held regional and international HR positions in different companies and industries, making a significant contribution to their talent development and management.

    Fanny holds a Master in Human Resources Management.
  • Ricardo Teixeira

    Head of Finance

    Ricardo has +12 years’ experience at GlaxoSmithKline in finance roles working in Latin America, Asia, Africa and Europe, leading finance transformation into a Business Partnership. He has a proven track record turning around businesses, improving efficiencies to drive high growth agendas.

    Ricardo holds a BSc in Business Administration from the University of Nova de Lisboa and a background in Audit at KPMG.

Board of Directors

  • Dr Ronald L. Goode

    Chairman of the Board

    Ronald L. Goode, PhD., was appointed non-executive chairman of Labatec in December 2018. He is currently President & CEO of his own consulting company The Goode Group. Dr. Goode is a very successful executive with considerable expertise in US and multinational operations, whose extensive experience in e.g. business development, clinical drug development has benefited multiple public, private and non-profit Boards and their companies.
    Dr. Goode served as President and CEO of two public companies (Unimed Pharmaceuticals, Inc. and eXegenics Inc, of which he was also Chairman). Other public companies of which he has served as a Director include Genitope Corporation, Vitro Diagnostics, Inc., Hokuriku Seiyaku and Hikma Pharmaceuticals (London Stock Exchange Listing: “HIK” and a member of the “FTSE 100” stock index).

    Dr. Goode holds a PhD. from the University of Georgia and brings more than 40 years of experience in the pharmaceutical industry.
  • Peter Grant

    Peter Grant is Chairman of LiDCO Group PLC and Non-Executive Director and Chair of the Audit and Risk Committee at Abzena PLC. He joined Skyepharma as Chief Financial Officer in 2006, becoming Chief Executive from 2012 until its merger with Vectura Group PLC in 2016. He has also held senior roles at Voice Commerce Group, Eurodis Electron PLC, WorldPay PLC, Molins PLC and the General Electric Company plc group of companies.

    Peter holds an MA in Mathematics from the University of Oxford and qualified as a Chartered Accountant with Peat, Marwick, Mitchell (now KPMG) in London.
  • Dr Ishaq Al Hajiri

    Dr Al Hajiri has spent over 20 years at Hikma Pharmaceuticals PLC in various management positions, most notably as Chairman of Al Jazeera Pharmaceuticals in Saudi Arabia (Hikma KSA).
  • Jostein Davidsen

    Elected to the Labatec board in July 2017, Jostein Davidsen brings 30 years of experience from the international pharmaceutical industry, most recently serving as the Chief Executive Officer of Acino Pharma AG in Switzerland. Jostein founded NYCOMED Russia – CIS, which became one of the leading companies in the Russian – CIS pharmaceutical market, and was named the world’s second most influential pharma-industry leader in Emerging Markets by Scrip (the pharmaceutical international news wire).

    Jostein studied at Oslo School of Business and Administration and has completed several Executive Management and Board programmes at IMD, Lausanne, Switzerland.
  • Ken Jones

    Ken Jones joined Innoture Ltd in June 2016 as Chief Executive Officer to take the company to its next level of growth. He previously spent 11 years at Astellas as President and CEO – EMEA operations, and prior to that, 17 years at Allergan in senior positions in the US, UK, Europe and Japan.

    With 30 years of pharmaceutical and medical device industry experience at global, regional and national level, Ken is a strategic thinker. He has also strong marketing, sales, market access and commercial capabilities.

Get in touch

Would you like to discuss a collaboration or partnership project? Get in touch with us at partnering@labatec.ch or connect with us at one of the upcoming events.

For other enquiries, please visit our contact page.